Discovering New Therapies & Preventions for Respiratory Health


 
LRRI offers state-of-the-art capabilities to the pharmaceutical and biotechnology industries for developing new therapies and preventive measures. LRRI’s expertise and in-depth experience allows customization of processes and protocols for optimal study results. We operate using both fee-for-service and collaborative arrangements.
 


 

Innovative LRRI capabilities include:

  • Proof-of-principle efficacy studies in small and large animal models of asthma, COPD/emphysema, fibrosis, and pulmonary hypertension
  • Animal models of viral respiratory disease (RSV, influenza, metapneumovirus)
  • Orthotopic lung cancer models
  • Multiple imaging modalities

Other more traditional contract services are:

  • Medicinal aerosol generation and measurement
  • Analytical and bioanalytical chemistry
  • Early metabolism studies
  • Pharmacokinetic and pharmacodynamic distribution studies
  • Traditional safety toxicology and pharmacology studies

Bench to Bedside:  The above studies can be designed to satisfy the preclinical (trial) safety requirement of the FDA and other regulatory bodies.  What sets LRRI apart from other research facilities is a wholly owned clinical trials company, Lovelace Scientific Resources.   In addition, LRRI’s clinical radiotracer imaging capabilities (SPECT-gamma camera) provide a realistic bench-to-bedside paradigm for the NIH and the pharmaceutical and biopharmaceutical industry to use in any phase of the drug development process.

Gene Therapy Resource Program, Pharmacology/Toxicology Core, NHLBI. LRRI provides a comprehensive research facility for conducting biodistribution and/or safety testing of gene vector products. Results of the gene vector testing will support development of human clinical trials. The pharmacology and biodistribution studies assess vector tropism, gene expression efficiency and kinetics, and vector clearance. The toxicology studies identify any adverse effects of the gene product transfer. Identification of an effective therapeutic dose from pharmacology studies coupled with knowledge of the dose causing no adverse effects provides a therapeutic index for development of clinical trials strategies. For more information view the GTRP web site.